Crucell’s strong product portfolio is supported through a range of patented technologies. Our cutting-edge technology platforms enable the discovery, development and production of vaccines, therapeutic proteins, and gene therapy products.

PER.C6® Technology

PER.C6^® technology is Crucell’s core proprietary technology. With over 45 commercial licenses issued on PER.C6^® technology, Crucell has set new industry standards for the development and industrial-scale manufacturing of vaccines, recombinant proteins including monoclonal antibodies, and gene therapy products. Read more

Vaccine Technology

Crucell employs a number of proprietary technologies to develop vaccines against viruses, parasites and bacteria. These technologies include:

• PER.C6® Technology
• AdVac® Technology
• Virosome Technology
• Recombinant Paramyxovirus Technology
• Hansenula polymorpha Technology

 

Read more

Protein Technology

Crucell employs a number of proprietary technologies to develop therapeutic proteins, including monoclonal antibody products. These technologies include:

• PER.C6® Technology
• STAR® Technology
• MAbstract® Technology

 

Read more

Quick Links

Products

R&D

Partners